by Claire | Oct 23, 2022 | Uncategorized
DIADEM AWARDED PATENT IN CHINA FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TECHNOLOGY THAT ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE —AlzoSure® Accurately Predicts Progression to Alzheimer’s Disease Up to Six Years Earlier than Current Diagnostic Methods—...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —AlzoSure® Predict Identifies Individuals Who Will Progress to Alzheimer’s Disease (AD) Up to Six Years...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS DATA AT 22ND INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY HIGHLIGHTING ITS BLOOD-BASED BIOMARKER TEST IS 84% CONCORDANT WITH AMYLOID BRAIN IMAGING —Further Analysis of Clinical Validation Data Shows Diadem’s AlzoSure® Predict Is Highly...
by Claire | Oct 23, 2022 | Uncategorized
EUROPEAN INVESTMENT BANK TO PROVIDE A €7.5 MILLION LOAN TO SUPPORT FURTHER RESEARCH AND DEVELOPMENT OF DIADEM’S ALZOSURE® PREDICT BLOOD TEST FOR ALZHEIMER’S DISEASE • First CE-IVD-marked blood test that predicts likely progression to Alzheimer’s disease up to six...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES FIRST CLOSING OF €10 MILLION EQUITY FINANCING FOR ITS ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR ALZHEIMER’S DISEASE —CDP Venture Capital and Panakès Partners Leading Equity Financing in Association with Recent €7.5M European Investment Bank Venture...
